Profile of nimotuzumab in the treatment of high-grade glioma

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 819-825

  Yang, Qun Ying ^a   Guo, Cheng Cheng ^a   Chen, Zhong Ping ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Chemotherapy; High grade gliomas; Nimotuzumab; Radiotherapy

Indexed keywords

CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; LAPATINIB; NAVELBINE; NIMOTUZUMAB; NIMUSTINE; PANITUMUMAB; PLACEBO; PREDNISONE; PROCARBAZINE; TEMOZOLOMIDE; TENIPOSIDE;

ACNE; ALLERGIC REACTION; ANOREXIA; APHASIA; ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CHEMORADIOTHERAPY; CHILDHOOD CANCER; CHILL; DIZZINESS; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EPENDYMOBLASTOMA; EVENT FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOGENICITY; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PONTINE GLIOMA; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREMOR; UNSPECIFIED SIDE EFFECT;

EID: 84929408366     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S60032     Document Type: Article

References (22)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996.
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466.
3. Jarvela S, Helin H, Haapasalo J, et al. Amplifcation of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situhybridization: association with clinicopathological features and patient survival. Neuropathol Appl Neurobiol. 2006;32:441–450.
4. Viana-Pereira M, Lopes JM, Little S, et al. Analysis of EGFR overexpression, EGFR gene amplifcation and the EGFRvIII mutation in Portuguese high-grade gliomas. Anticancer Res. 2008;28:913–920.
5. Mazzoleni S, Politi LS, Pala M, et al. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res. 2010;70(19):7500–7513.
6. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012–2024.
7. Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. 2009;1(1):41–48.
8. Diaz-Miqueli A, Martinez GS. Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities. Onco Targets Ther. 2013;6:931–942.
9. Bode U, Massimino M, Bach F, et al. Nimotuzumab treatment of malignant gliomas. Expert Opin Biol Ther. 2012;12(12):1649–1659.
10. Ramos TC, Figueredo J, Catala M, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther. 2006;5(4):375–379.
11. Qin D, Ou G, Mo H, et al. Improved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier: clinical results. Int J Radiat Oncol Biol Phys. 2001;51:959–962.
12. Ramos-Suzarte M, Rodriguez N, Oliva JP, et al. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumours of epithelial origin, part II: clinical trials safety and diagnostic efficacy. J Nucl Med. 1999;40:768–775.
13. Hong J, Peng Y, Liao Y, et al. Nimotuzumab prolongs survival in patients with malignant gliomas: a phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab. Exp Ther Med. 2012;4(1):151–157.
14. Bartels U, Wolff J, Gore L, et al. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro Oncol. Epub May 20, 2014.
15. Yang QY, Shen D, Sai K, et al. [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas]. Zhonghua Zhong Liu Za Zhi. 2011;33(3):232–235. Chinese.
16. Solomon MT, Miranda N, Jorrín E, et al. Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience. Cancer Biol Ther. 2014;15(5):504–509.
17. Massimino M, Biassoni V, Miceli R, et al. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neurooncol. 2014;118(2):305–312.
18. Wang Y, Pan L, Sheng XF, et al. Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: first results in Chinese patients. Asia Pac J Clin Oncol. Epub January 24, 2014.
19. Saurez G, Cabanas R, Zaldívar M, et al. Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007.MEDICC Rev. 2009;11(3):27–33.
20. Cabanas R, Saurez G, Rios M, et al. Treatment of children with high grade glioma with nimotuzumab: a 5-year institutional experience. MAbs. 2013;5(2):202–207.
21. Solomón J et al. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer. 2013;13:299.
22. Westphal M, Bach F. Final results of a randomized phase III trial of nimotuzumab for the treatment of newly diagnosed glioblastoma in addition to standard radiation and chemotherapy with temozolomide versus standard radiation and temoziolamide. ASCO Annual Meeting; June 1–5, 2012; Chicago, IL, USA. J Clin Oncol. 30(Suppl):Abstr 2033.